Adverse Drug Reaction Classification System

         

Pharmaceutical Information
Drug Name Neostigmine
Drug ID BADD_D01553
Description A cholinesterase inhibitor used in the treatment of myasthenia gravis and to reverse the effects of muscle relaxants such as gallamine and tubocurarine. Neostigmine, unlike physostigmine, does not cross the blood-brain barrier.
Indications and Usage Neostigmine is used for the symptomatic treatment of myasthenia gravis by improving muscle tone.
Marketing Status approved; vet_approved
ATC Code N07AA01; S01EB06
DrugBank ID DB01400
KEGG ID D08261
MeSH ID D009388
PubChem ID 4456
TTD Drug ID D08USJ
NDC Product Code 71872-7178; 43598-528; 43598-529
UNII 3982TWQ96G
Synonyms Neostigmine | Synstigmin | Proserine | Prozerin | Polstigmine | Neostigmine Bromide | Bromide, Neostigmine | Syntostigmine | Neostigmine Methylsulfate | Methylsulfate, Neostigmine | Prostigmine | Prostigmin
Chemical Information
Molecular Formula C12H19N2O2+
CAS Registry Number 59-99-4
SMILES CN(C)C(=O)OC1=CC=CC(=C1)[N+](C)(C)C
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice.
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Abdominal pain07.01.05.002--
Agitation17.02.05.012; 19.06.02.001--
Anaphylactic shock10.01.07.002; 24.06.02.004---
Arrhythmia02.03.02.001---
Arthralgia15.01.02.001--
Asthenia08.01.01.0010.000699%-
Atrioventricular block02.03.01.002---
Atrioventricular block complete02.03.01.0030.000269%
Bradycardia02.03.02.0020.001487%-
Bronchospasm10.01.03.012; 22.03.01.004--
Cardiac arrest02.03.04.0010.000842%
Cardiovascular disorder02.11.01.010; 24.03.02.009---
Chest discomfort02.02.02.009; 08.01.08.019; 22.12.02.002---
Coma17.02.09.001---
Dermatitis23.03.04.002---
Diarrhoea07.02.01.001--
Dizziness02.11.04.006; 17.02.05.003; 24.06.02.007--
Drug ineffective08.06.01.0060.003207%-
Drug interaction08.06.03.0010.000269%-
Dry mouth07.06.01.002--
Dysarthria17.02.08.001; 19.19.03.001--
Dyspnoea02.11.05.003; 22.02.01.0040.000358%
Flatulence07.01.04.002--
Flushing08.01.03.025; 23.06.05.003; 24.03.01.002--
Gastrointestinal disorder07.11.01.001---
Gastrointestinal pain07.01.05.005--
Headache17.14.01.001--
Hyperhidrosis08.01.03.028; 23.02.03.004--
Hypersensitivity10.01.03.003--
Hypotension24.06.03.0020.000179%
The 1th Page    1 2 3    Next   Last    Total 3 Pages
ADReCS-Target
Drug Name ADR Term Target
Tip:  Drug Name  ADR Term  Protein  Variation  Gene